Filing Details
- Accession Number:
- 0001209191-19-034738
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-06-05 16:21:48
- Reporting Period:
- 2019-06-03
- Accepted Time:
- 2019-06-05 16:21:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1396814 | Pacira Biosciences Inc. | PCRX | Pharmaceutical Preparations (2834) | 510619477 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1709330 | Richard Scranton | C/O Pacira Biosciences, Inc. 5 Sylvan Way, Suite 300 Parsippany NJ 07054 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-06-03 | 3,010 | $10.52 | 23,111 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2019-06-03 | 12,500 | $10.81 | 35,611 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-06-03 | 15,510 | $43.21 | 20,101 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-06-03 | 3,010 | $0.00 | 3,010 | $10.52 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-06-03 | 12,500 | $0.00 | 12,500 | $10.81 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2022-03-02 | No | 4 | M | Direct | |
| 0 | 2022-06-05 | No | 4 | M | Direct |
Footnotes
- The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.14 to $43.49, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The stock options are fully vested.
Billionaire Hedge Funds
